Day: August 6, 2020

WOBURN, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) — Yield10 Bioscience, Inc. (NASDAQ: YTEN), an agricultural bioscience company, announced today that the Company will report its second quarter 2020 financial results and provide a corporate update on Tuesday, August 11, 2020.Management will host a conference call on Tuesday, August 11, 2020 at 4:30 p.m. ET to review financial results, share corporate highlights, and provide an overall business update. Following management’s formal remarks, there will be a question and answer session.To listen to the conference call, interested parties within the U.S. should call 1-877-709-8150. International callers should call +1-201-689-8354. The call will also be available through a live webcast, and will reference a slide deck, both of which may be accessed through the investor relations section...

WILMINGTON, Del., Aug. 06, 2020 (GLOBE NEWSWIRE) — InterDigital, Inc. (NASDAQ:IDCC), a mobile and video technology research and development company, today announced results for the second quarter ended June 30, 2020.Second Quarter 2020 Financial HighlightsSecond quarter 2020 recurring revenue was $85.2 million, compared to recurring revenue of $74.4 million in second quarter 2019, a 15% increase.  This increase was driven by new patent license agreements signed over the last twelve months, including with Huawei and ZTE. Second quarter 2020 total revenue was $104.5 million, compared to $75.6 million in second quarter 2019. The increase was primarily driven by the signing of a new fixed-fee patent license agreement with Huawei in second quarter 2020.Second quarter 2020 operating expenses were $72.6 million, compared to $66.7 million...

Tampa, FL, Aug. 06, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — B2Digital Incorporated (the “Company” or “B2Digital”) (OTCMKTS:BTDG), the premier development league for mixed martial arts (“MMA”), issues the following letter to shareholders on behalf of the CEO:Dear Valued Shareholder,Allow me to begin today by expressing our most sincere gratitude to our faithful shareholders for your loyalty, patience, and commitment. Today, I would like to provide you with a more thorough and detailed understanding of our vision, our current status and near-term prognosis, further insights into our emerging model, what we have recently accomplished, and what we are focused on achieving next.First off, we are extremely excited about the path ahead, and about returning to our pre-Covid operating assumptions, when we were just starting to ride...

SOLANA BEACH, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) — Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the second quarter ended June 30, 2020.“The recent FDA approval of Gimoti, the first and only outpatient treatment option that bypasses the stomach to relieve symptoms in adults with acute and recurrent diabetic gastroparesis, marked the most significant milestone in our history,” said David A. Gonyer, R.Ph., President and CEO of Evoke Pharma. “We are currently focused on the commercial launch of Gimoti during the fourth quarter of 2020 with EVERSANA, our commercial partner. EVERSANA is working with us to fully implement our strategy, while leveraging their integrated suite of commercialization capabilities....

FLORHAM PARK, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the second quarter of 2020.“The second quarter was very productive for Phathom as we resumed new patient screening and enrollment in both our PHALCON-EE and PHALCON-HP Phase 3 trials and continued to make substantial progress in building our organization,” said Terrie Curran, President and Chief Executive Officer of Phathom.  “Our engagement with clinical sites has been extremely positive, and we’re encouraged by the ongoing enrollment in both trials to date.  While continuing to execute on our current development programs, we have also advanced our medical, commercial,...

SAN DIEGO, Aug. 06, 2020 (GLOBE NEWSWIRE) — Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced the appointment of Lance Kurata as Chief Legal Officer, starting August 10, 2020.  Mr. Kurata joins Arcturus from Mintz, where he was a partner in the Corporate Group and a member of the Life Sciences Practice Group.“Lance is widely recognized as a leading biotechnology focused attorney. His deep expertise in transactions and intellectual property will be particularly valuable as Arcturus continues to drive forward our differentiated messenger RNA therapeutic and vaccine platform and our pipeline of promising...

Smart Beverage Will Distribute Only Barfresh Products to Its Customers Including Over 800 SchoolsRelationship Expected to Initially Generate Revenue of $1 Million to $2 Million Annually In Current COVID-19 EnvironmentExcluding the COVID-19 Environment, Relationship Expected to Generate Revenue of $2 Million to $3 Million AnnuallyLOS ANGELES, Aug. 06, 2020 (GLOBE NEWSWIRE) — Barfresh Food Group, Inc. (the “Company” or “Barfresh”) (OTCQB: BRFH), a manufacturer of frozen, ready-to-blend and ready-to-drink beverages, announced it has entered into a strategic distribution relationship with Smart Beverage Inc., (dba Thirsty Coconut)., Inc. Smart Beverage will sell Barfresh’s full line of products, to include Twist & Go, and Bulk-Easy Pour, as well as sell and distribute Barfresh’s new range of WHIRLZ 100% juice Concentrates that...

DENVER, Aug. 06, 2020 (GLOBE NEWSWIRE) — Assure Holdings Corp. (the “Company” or “Assure”) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services, will hold a conference call on Friday, August 28, 2020, at 11:00 a.m. Eastern time to discuss its financial results for the second quarter ended June 30, 2020. The Company will report its financial results in a press release prior to the conference call.Assure’s executive chairman and CEO John Farlinger, CFO Trent Carman and Founder Preston Parsons will host the conference call, followed by a question and answer period.Date: Friday, August 28, 2020Time: 11:00 a.m. Eastern time (9:00 a.m. Mountain time)Toll-free dial-in number: 1-877-407-0792International dial-in number: 1-201-689-8263Conference ID: 13708176Please call the conference telephone number 5-10 minutes...

SEATTLE, Aug. 06, 2020 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that management will participate in a fireside chat at the virtual Canaccord Genuity 40th Annual Growth Conference on Thursday, August 13, 2020 at 8:30 a.m. Eastern Time.A live audio webcast of the session will be available from the investors section of the Neoleukin website at http://investor.neoleukin.com/events. An archived replay will also be available on the company website for at least 30 days following the event.About Neoleukin Therapeutics, Inc.Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology....

ATLANTA, Aug. 06, 2020 (GLOBE NEWSWIRE) — DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of innovative healthcare services and solutions to federal agencies, today announced that it will participate in the upcoming Canaccord Genuity Virtual Growth Conference on August 12, 2020.Additional information will be posted on the Company’s website when available, including a copy of the presentation material and webcast details. Institutional investors are welcome to contact the conference hosts to arrange one-on-one calls with management. About DLHDLH (NASDAQ:DLHC) serves federal government clients throughout the United States and abroad delivering technology enabled solutions in key health and human services programs. The Company’s seven core competencies include secure data analytics, clinical trials...